![Christopher O’Donnell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher O’Donnell
Directeur/Membre du Conseil chez
Adapsyn Bioscience, Inc.
Profil
Christopher O'Donnell , PHD is Executive Director, WRDM and Partner at Pfizer Ventures.
Chris is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer.
He currently has responsibility for Pfizer’s investments in Adapsyn, Bioscience Arkuda Therapeutics, Arrakis Therapeutics, Mitokinin, Parthenon Therapeutics, Pyxis Oncology (PYXS), Storm Therapeutics, and Strata Oncology.
He is also responsible for managing our investment in the Mission BioCapital and Phoenix Venture Partners funds.
His prior investment responsibilities include BioAtla (BCAB), Kymera Therapeutics (KYMR), Morphic Therapeutic (MORF) and Petra Pharma.
Chris brings 20+ years of scientific leadership, a strong track record of delivering clinical candidates across multiple disease areas and modalities, and proven ability to build and lead highly engaged teams.
He built and led the Applied Synthesis Technologies group within R&D to help accelerate the delivery of Pfizer’s small molecule portfolio.
Prior to that, Chris built and led Pfizer’s Antibody Drug Conjugate Oncology Medicinal Chemistry group which delivered new linker, payload and conjugation methods resulting in over 7 conjugates entering clinical development.
Chris started his career in the Neuroscience Medicinal Chemistry group where he invented and helped deliver numerous clinical candidates.
Chris received his BS in Chemistry from the University of Illinois-Urbana/Champaign and his PhD in Chemistry from the University of Wisconsin-Madison and joined Pfizer after completing post-doctoral studies at the University of California - Irvine
Postes actifs de Christopher O’Donnell
| Sociétés | Poste | Début |
|---|---|---|
Adapsyn Bioscience, Inc.
 Adapsyn Bioscience, Inc. BiotechnologyHealth Technology Operates as a biotechnology company focussed on the discovery and development of novel medicines | Directeur/Membre du Conseil | - |
Arkuda Therapeutics, Inc.
 Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing medicines to improve the lives of patients with neurological diseases | Directeur/Membre du Conseil | - |
Pfizer Venture Investments LLC
 Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments invests in companies located across the globe primarily in the United States. The firm focuses on companies operating in oncology, inflammation & immunology, cardiovascular, metabolic/Obesity and Vaccines sectors. It provides financing for seed, early and growth stage capital requirements with an investment size of USD 5 - 20 million. The firm make follow on financing and also acts as lead investor. | Private Equity Investor | 01/03/2018 |
STORM Therapeutics Ltd.
 STORM Therapeutics Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecule drugs through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases | Directeur/Membre du Conseil | - |
Strata Oncology, Inc.
 Strata Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures oncology drugs | Directeur/Membre du Conseil | - |
Incendia Therapeutics, Inc.
 Incendia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel class of anti-cancer therapies | Directeur/Membre du Conseil | - |
Santi Therapeutics, Inc.
 Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics to treat diseases | Directeur/Membre du Conseil | - |
Anciens postes connus de Christopher O’Donnell
| Sociétés | Poste | Fin |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Directeur/Membre du Conseil | 01/10/2021 |
| KYMERA THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Formation de Christopher O’Donnell
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
12
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments invests in companies located across the globe primarily in the United States. The firm focuses on companies operating in oncology, inflammation & immunology, cardiovascular, metabolic/Obesity and Vaccines sectors. It provides financing for seed, early and growth stage capital requirements with an investment size of USD 5 - 20 million. The firm make follow on financing and also acts as lead investor. | Finance |
Strata Oncology, Inc.
Strata Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures oncology drugs | Health Technology |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecule drugs through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases | Health Technology |
Kymera Therapeutics, Inc.
 Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
University of Illinois At Urbana–Champaign
 University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adapsyn Bioscience, Inc.
Adapsyn Bioscience, Inc. BiotechnologyHealth Technology Operates as a biotechnology company focussed on the discovery and development of novel medicines | Health Technology |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing medicines to improve the lives of patients with neurological diseases | Health Technology |
Pyxis Oncology, Inc.
 Pyxis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a preclinical oncology company focused on developing an arsenal of next-generation therapeutics | Health Technology |
Santi Therapeutics, Inc.
Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics to treat diseases | Health Technology |
Incendia Therapeutics, Inc.
Incendia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel class of anti-cancer therapies | Health Technology |
